The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

But following his election win this week it is looking increasingly likely that won’t happen and Donald Trump will once again ...

FT836 Preclinical Data Shows Robust Antigen-mediated Expansion, Functional Persistence, and Durable Anti-tumor Activity in ...

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...

Approval of the CD19 chimeric antigen receptor T-cell therapy (CAR T) — which, according to Autolus, was specifically “designed to have a ‘fast-off’ kinetic” to minimize excessive activation of the ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

TCRclub integrates scRNA-seq and scTCR-seq data by local harmony to identify functionally similar T cell groups, termed ...

Weill Cornell Medicine researchers have discovered a way ovarian tumors cripple immune cells: by tampering with their ability ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, ...